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The prevention or delay of the onset of age-related
diseases prolongs survival and improves quality of
life while reducing the burden on the health care
system. Activation of sirtuin 1 (SIRT1), an NAD+-
dependent deacetylase, improves metabolism and
confers protection against physiological and cogni-
tive disturbances in old age. SRT1720 is a specific
SIRT1 activator that has health and lifespan benefits
in adult mice fed a high-fat diet. We found extension
in lifespan, delayed onset of age-related metabolic
diseases, and improved general health in mice fed a
standard diet after SRT1720 supplementation. Inhibi-
tion of proinflammatory gene expression in both liver
and muscle of SRT1720-treated animals was noted.
SRT1720 lowered the phosphorylation of NF-kB
pathway regulators in vitroonlywhenSIRT1was func-
tionally present. Combined with our previous work,
the current study further supports the beneficial ef-
fects of SRT1720 on health across the lifespan in
mice.
INTRODUCTION
Manyof the chronic diseases that exist in older adults constitute a
highly significant social and economic burden to the community.
Long-term illness, diminished quality of life, and increased health
care costs are all challenges that older adults are facing. Sirtuin 1
(SIRT1), an NAD+-dependent deacetylase, is one of seven
mammalian sirtuins and is known to play an important role
in maintaining metabolic homeostasis in multiple tissues (Baur836 Cell Reports 6, 836–843, March 13, 2014 ª2014 The Authorset al., 2012). SIRT1 has been proposed as an antiaging protein,
and its activation results in health benefits in multiple organisms
(Baur et al., 2012). Pharmacological interventions aimed at
increasing SIRT1 activity have been found to slow the onset of
aging and delay age-associated diseases. There is mounting
evidence that overexpression of SIRT1 in mice and use of
small molecule activators of SIRT1, such as resveratrol and
SRT1720, enhance insulin sensitivity and protect against diet-
induced impairments in mitochondrial capacity and oxidative
metabolism in laboratory animals (Banks et al., 2008; Feige
et al., 2008; Milne et al., 2007; Pfluger et al., 2008). Even though
SIRT1 activators improve health and extend lifespan of mice
maintained on a high-fat diet (Baur et al., 2006; Minor et al.,
2011), there has yet to be a demonstration of both improvements
in lifespan and healthspan in mice fed a standard diet (SD). Re-
sveratrol improves healthspan of SD-fed mice; yet, no effect on
lifespan was noted in C57BL6/J mice (Pearson et al., 2008) or
in genetically heterogeneous mice (Strong et al., 2013). Other
compounds that extend lifespan in mice include the immuno-
modulatory drug rapamycin (Harrison et al., 2009) and the insu-
lin-sensitizing agent metformin. However, chronic administration
of rapamycin induces glucose intolerance, insulin resistance, and
incidence of diabetogenic effects (Deblon et al., 2012; Houde
et al., 2010; Lamming et al., 2012). Similarly, metformin is associ-
ated with adverse side effects, including lactic acidosis and kid-
ney dysfunction in a dose-dependent manner (Martin-Montalvo
et al., 2013). Here, we show that SRT1720 supplementation
extends survival and improves health inmice fed a standard diet.
RESULTS AND DISCUSSION
To test the effect of SRT1720 on the health and lifespan of
C57BL6/J mice, these animals were fed either a high-fat diet
(HFD) or a standard AIN-93G diet (SD) supplemented with
Figure 1. SRT1720 Extends Lifespan and
Improves Health in Mice Fed a Standard
Diet
(A) Kaplan-Meier survival curves for mice fed
either a standard diet (SD) or high-fat diet (HFD)
supplemented without or with SRT1720 (SD-
SRT1720, HFD-SRT1720).
(B) Average body weight over the study.
(C) Average daily caloric intake over the study.
(D) Percentage fat mass measured by nuclear
magnetic resonance spectroscopy at 13 months
of age.
(E) Respiratory exchange ratio (RER).
(F) Rotarod performance.
Data are shown as mean ± SEM. *p % 0.05 in
comparison to diet without SRT1720.100 mg/kg body weight of SRT1720 beginning at 6 months of
age for the remainder of their life. SRT1720 treatment signifi-
cantly extends mean lifespan of mice on both diets (Figure 1A).
Survival among the SD-fed groups was significantly different
as assessed using the nonparametric log-rank (Mantel-Haens-
zel) test (c2 = 4.168, p = 0.0412). Mean lifespan was increased
8.8%, and we observed a trend toward an increase in median
lifespan of 5 weeks (Su and Wei, 1993) with SRT1720 supple-
mentation (c2 = 2.77, p = 0.096). However, there was no differ-
ence in 90th percentile survival (Wang et al., 2004) despite the
overall significant effect on lifespan. These data are consistent
with the notion that in the absence of ametabolic insult, interven-
tions such as SRT1720 will have a more pronounced effect in
delaying the onset of age-associated diseases. Survival was
significantly lower in HFD-fed mice based on the nonparametric
log-rank (Mantel-Haenszel) test (c2 = 5.470, p = 0.0193), and
SRT1720 supplementation increased mean lifespan by 21.7%,Cell Reports 6, 836–84in agreement with our previous study (Mi-
nor et al., 2011), although maximum life-
span did not change (Figure 1A). Median
survival was significantly increased by
22 weeks in HFD-fed mice treated with
SRT1720 (c2 = 5.23, p = 0.022), indicating
an improvement in general health in
these mice (Figure 1A). The hazard ratio
for death was significantly reduced with
SRT1720 treatment (HR = 0.73, 95%con-
fidence interval [0.59, 0.90], p = 0.0034),
indicating a positive effect of SRT1720
on improving lifespan in mice. SRT1720
significantly reduced the average body
weight of HFD-fed mice (Figure 1B)
despite no difference in daily caloric
intake (Figure 1C) or food consumption
(Figure S1A). As expected, mice on HFD
weighed significantly more than their
SD-fed counterparts across the course
of the study (Figure S1B). SRT1720 sup-
plementation also reduced both average
body weight (Figure 1B) and body weight
of SD-fed animals (Figure S1B) withoutimpacting on daily caloric intake (Figure 1C). Treatment with
SRT1720 significantly reduced body fat percentage in SD-fed
animals (Figure 1D), despite no difference in lean-to-fat ratio (Fig-
ure S1C). However, the lack of difference for either parameter in
HFD-treated mice is in contrast with our previous study (Minor
et al., 2011), which may be due to the time point at which the
treatment was started (6 months versus 12 months).
Recent studies have illustrated the beneficial cardioprotective
effects of SRT1720 against ischemia-reperfusion injury and
the loss of cardiac function that occurs with aging (Tong et al.,
2013). SRT1720 also confers protection from atherosclerosis
in vitro (Zeng et al., 2013) via SIRT1 activation. The synchrony
in circadian rhythms leads to increased longevity and improved
health (Froy, 2011). Interestingly, SRT1720 is essential for
the proper regulation of circadian rhythm in the liver of SD-fed
mice through a SIRT1-dependent mechanism (Bellet et al.,
2013). Although some controversy exists concerning the3, March 13, 2014 ª2014 The Authors 837
Figure 2. SRT1720 Improves the Quality of Life of SD-Fed Mice
(A) Cataract formation as assessed by lens opacity classification.
(B) Oral glucose tolerance test with area under the curve (inset).
(C) The homeostatic model assessment calculation of insulin resistance
(HOMA-IR) and serum biochemical markers.
Data are shown as mean ± SEM. *p% 0.05 in comparison to SD diet without
SRT1720.specificity of SRT1720 toward SIRT1 (Huber et al., 2010; Pacho-
lec et al., 2010), the notion that SIRT1 is a target of SRT1720
is supported by recent data showing that it activates SIRT1 via
a direct allosteric mechanism (Hubbard et al., 2013). Taken
together, these results illustrate the involvement of multiple
SIRT1-dependent mechanisms in the biological actions of
SRT1720.
We assessed metabolism using the Comprehensive Lab
Animal Monitoring System (CLAMS) and found that SRT1720
supplementation significantly lowered respiratory exchange ra-
tio (RER) in SD-fed animals during the light cycle, with a trend to-
ward a reduction during the dark cycle (Figure 1E). No difference
in locomotor activity between groupswasobserved (FigureS1D).
The RER for HFD-fed mice was close to 0.7, indicating a prefer-
ence for fatty acid oxidation (Figure 1E). Interestingly, increased
fatty acid oxidation in SRT1720-treated SD-fed mice, as evi-
denced by a decrease of RER, could explain the lower percent-
age of fat mass in these animals (Figure 1D). It was important to
ascertain whether there was improvement in the quality of life of
SRT1720-treated mice through assessment of balance and mo-
tor coordination. SRT1720 significantly improved rotarod perfor-
mance at 13 and 18 months of age in SD-fed mice, with a nearly
significant (p = 0.08) improvement in performance at 24 months
of age (Figure 1F). No beneficial effects of SRT1720 were
observed in HFD-fed mice (Figure 1F). Although it is recognized
that there is both a learning and body weight component to the
rotarod performance test, a recent study has shown that
improvement in rotarod performance can be independent of
body weight and that diet may have a larger effect on neurobe-
havior than either learning or body weight (Kova´cs and Pearce,838 Cell Reports 6, 836–843, March 13, 2014 ª2014 The Authors2013). Overall these data indicate that SRT1720 improves mus-
cle function and motor coordination over the life of SD-fed mice.
For the remainder of the study, we focused on the effects of
SRT1720 on various metabolic variables in SD-fed mice.
Because aging is associated with functional andmetabolic de-
clines, we assessed the effects of SRT1720 on several variables
of aging. The increase in cataract formation with age has been
attributed, in part, to the accumulation of reactive oxygen spe-
cies (Wolf et al., 2005). Here, a marked reduction in cataract
opacity was observed in SRT1720-treated SD-fed mice (Fig-
ure 2A), which is consistent with our previous study on resvera-
trol (Pearson et al., 2008).
Another hallmark feature of aging is the increase in blood
glucose and insulin levels, which leads to type 2 diabetes,
cardiovascular disease, and nonalcoholic fatty liver disease.
In this study, an oral glucose tolerance test was performed
to determine whether SRT1720 supplementation improved
glucose disposal in SD-fed mice (Figure 2B). Our results indi-
cated significant reduction in area under the curve values,
which are consistent with greater glucose disposal in response
to SRT1720 (Figure 2B, inset). Although not statistically signifi-
cant, the reduction in the Homeostatic Model Assessment of In-
sulin Resistance (HOMA-IR) index was indicative of improved
insulin sensitivity in SRT1720-treated animals (Figure 2C).
Recent work has reported that SRT1720 lowers insulin resis-
tance in mouse models of obesity (Minor et al., 2011; Yamazaki
et al., 2009), which may be due to an enhancement of glucose-
stimulated insulin secretion by SRT1720. This biological
response was not measured in the current study. Our results
are consistent with two previous studies showing that lifelong
resveratrol supplementation and short-term SRT1720 treatment
of HFD-fed mice both elicit beneficial effects on insulin sensi-
tivity and protect against diet-induced impairments in mito-
chondrial capacity and oxidative metabolism in vivo (Feige
et al., 2008; Pearson et al., 2008). Total cholesterol and low-
density lipoprotein levels were lower in SRT1720-treated mice
fed an SD (Figure 2C), which may be due to reduced expression
of lipogenic enzymes that occur with SRT1720 treatment
(Yamazaki et al., 2009). The ability of SRT1720 to influence
serum lipid profile may contribute to an improvement in risk fac-
tors for metabolic syndrome that occurs as part of the normal
progression of aging. Thus, mechanisms of lifespan and health-
span extension by SRT1720 could be linked to protection
against age-associated metabolic and functional decline in
laboratory mice.
SRT1720 treatment did not alter the number of pathologies in
SD-fed mice on gross postmortem pathology screens (Table
S1). Although the incidence of hepatocellular carcinoma and
glomerulonephritis appeared higher in the SRT1720-treated
group (Table S1), the mean age at which necropsy was per-
formed was 10 weeks later, consistent with the notion that
SRT1720 delays the onset of pathologies allowing mice to live
a longer and healthier life. The incidence of lymphoma was not
assessed in these mice. Upon further histological analysis of tis-
sues by a blinded pathologist (Table S2; Figure S2), we observed
a significant reduction in steatosis in the SRT1720-treated mice
relative to the SD-fed animals, despite a small but significant
increase in lymphocyte infiltration in the kidneys (Table S2).
SRT1720 has been shown to be effective in reducing HFD-
induced pathologies (Minor et al., 2011), atherosclerosis (Zeng
et al., 2013), and myocardial infarction (Tong et al., 2013).
Although overexpression of SIRT1 confers a multidrug resis-
tance phenotype in various cancer cell lines in vitro (de Jong
et al., 2011; Oh et al., 2010; Zhu et al., 2012), pharmacological
activation of SIRT1 by SRT1720 has been associatedwith reduc-
tion inmultiplemyeloma tumor growth (Chauhan et al., 2011), but
increased lung metastasis of breast cancer cells in a mouse
xenograft model (Suzuki et al., 2012). Harmful effects of this
kind warrant further studies on dosage, timing, and actions in
various tissues of SRT1720 relevant to the development of ther-
apeutically useful SIRT1 activators. In the study herein, low levels
of serummarkers of hepatic and renal function—AST, creatinine,
and CK—were found with SRT1720 treatment (Figure 2C), indi-
cating that the compound was well tolerated. To ensure that
the ingested SRT1720 reached adequate circulating concentra-
tions, the serum levels of SRT1720 were measured in the morn-
ing and evening and were found to be 193 ± 30.0 and 339 ±
23.0 ng/ml, respectively, consistent with the feeding cycle of
the mice and with our previous study of HFD-fed mice (Minor
et al., 2011). To date, there has been no correlation between
STAC concentrations (resveratrol or SRT1720) in vivo and acti-
vation of SIRT1 in vitro, the reason being that there is controversy
surrounding themethods for measuring SIRT1 enzymatic activity
(Dominy et al., 2013). Thus far, the measurement of the steady-
state acetylation status of select sirtuin substrates in vivo (e.g.,
PGC-1a, p53, NF-kB, and others) remains an important tool for
evaluating changes in sirtuin activity (Dominy et al., 2013). Based
on our NF-kB data (see below), we propose that the measured
plasma concentration of SRT1720 in treated mice is sufficient
to activate SIRT1 in vivo.
Whole-genome DNA microarrays were performed on liver and
muscle samples of SD-fed mice supplemented or not with
SRT1720. Principal component analysis showed a distinct sep-
aration of both treatment groups, with the effect of SRT1720
supplementation being more pronounced in the muscle tissue
(Figure 3A versus 3B). The top ten up- and downregulated genes
in both tissues are shown in Table S3, with the complete data set
made available at http://ncbi.nlm.nih.gov/geo/. Among the top
upregulated genes, members of the cytokine-induced STAT in-
hibitor (CIS) family (e.g., suppressor of cytokine signaling 2
[SOCS2] and cytokine-inducible SH2-containing protein
[CISH]), which are associated with suppression of the inflamma-
tory response (Kubo et al., 2003), were significantly higher in the
liver and muscle of SRT1720-treated mice. Similarly, a 7-fold in-
crease in hepatic expression of cytochrome P450 1A2, which
has a role in xenobiotic, cholesterol, and lipid metabolism (Haf-
ner et al., 2011), was observed in SRT1720-treated mice and
may explain the lower circulating serum cholesterol and LDL
levels in these animals. These results are consistent with a recent
report showing that SRT1720 ameliorates fatty liver through a
reduction in lipogenic enzyme expression in monosodium gluta-
mate-treatedmice (Yamazaki et al., 2009). Lipocalin 2 (Lcn2) and
serum amyloid A1 and A2 (Saa1, Saa2), which are involved in
innate immunity and the acute phase response, respectively,
were the top three most downregulated genes in the liver of
SRT1720-treated animals. Downregulation of the cytokine-inducible transcription factor, Ankyrin repeat domain 1 (Ankrd1),
was observed in themuscle following SRT1720 supplementation
(Table S3).
The effect of SRT1720 on gene expression was further inves-
tigated using parametric analysis of gene set enrichment (PAGE)
(Figure 3C). Interestingly, the negative transcriptional effect of
SRT1720 was stronger in muscle than in liver. The expanded
list of top up- and downregulated pathways in the liver and mus-
cle of SRT1720-treated mice are presented in Tables S4 and S5.
Notably, ribosomal proteins were the most upregulated path-
ways in liver (Table S4), and alterations in ribosomal biology
and translation are tightly linked to longevity in other organisms
(Heeren et al., 2009; Houtkooper et al., 2013; Rogers et al.,
2011), which may provide another mechanism through which
SRT1720 exerts its prolongevity effects. One of the top path-
ways to be altered by SRT1720 supplementation in both liver
and muscle was the inflammation pathway, and quantitative
RT-PCR analysis showed significant reduction in select proin-
flammatory mediators in both tissues when compared to SD-fed
control animals (Figure 3D). Consistent with this idea, circulating
tumor necrosis factor (TNF)-a levels were lower in the SRT1720
cohort (Figure 3E), and a number of NF-kB target genes were
among the top downregulated genes following SRT1720 supple-
mentation (Table S3). Similarly, western blotting of liver lysates
illustrated the significant reduction in protein levels encoding
for p65Rel and two known targets of NF-kB, COX2, and BAX
(Figure 3F). No alteration in SIRT1 protein expression was
observed. Although the acetylation status of canonical SIRT1
targets was not directly assessed, these results led us to hypoth-
esize that SRT1720 may inhibit NF-kB signaling via SIRT1
activation.
To explore the molecular mechanisms underlying SRT1720
control of inflammatory signaling, murine embryonic fibroblasts
(MEFs) derived from SIRT1-knockout mice were used for
cDNA microarray analysis (Figure 4; Table S6) in conjunction
with phosphoantibody microarray (Table S7). Using the latter
method, it has previously been demonstrated that SIRT1 dele-
tion is associatedwith constitutive activation of the proinflamma-
tory NF-kB pathway (Bernier et al., 2011). Overexpression of
SIRT1 is associated with reduced NF-kB activity in mice (Pfluger
et al., 2008), whereas SIRT1 activation by SRT1720 reduces
expression of NF-kB and its targets in foam cells (Zeng et al.,
2013) and multiple myeloma cells (Chauhan et al., 2011). Here,
it was found that the expression level of a few genes was influ-
enced by SRT1720 in a SIRT1-independent manner (e.g., Id2),
whereas the expression of other genes, including Has2,
Gadd45a, Ddit3, Thbs1, and Ifitm3, required SIRT1 following
MEF stimulation with SRT1720 (Table S6). Importantly,
SRT1720 induced significant changes in the phosphorylation
status of several proteins involved in NF-kB activation in wild-
type MEFs, but not Sirt1-KO MEFs (Table S7). Given that low-
grade chronic inflammation is believed to contribute to aging
and age-related diseases (Franceschi et al., 2000), our results
indicate that SRT1720 may keep nonobese mice healthier and
extend their mean lifespan by spurring robust inflammatory de-
fense. Indeed, SRT1720 exerts antiinflammatory properties in
mousemodels of asthma (Ichikawa et al., 2013) and emphysema
(Yao et al., 2012).Cell Reports 6, 836–843, March 13, 2014 ª2014 The Authors 839
Figure 3. SRT1720 Elicits Differential Gene Expression Profiles in the Liver and Muscle of SD-Fed Mice
(A and B) Principal component analysis (PCA) was performed on liver (A) and skeletal (B) muscle of SD-fed mice supplemented without and with SRT1720.
(C) Parametric analysis of gene-set enrichment (PAGE) analysis was performed on microarray data. Columns show significantly up- (red) and downregulated
(blue) pathways following SRT1720 supplementation.
(D)mRNAexpressionanalysis in liver andskeletalmusclebyquantitative real-timePCR.Relative expression valueswere normalized to thoseofSD-fedcontrolmice.
(E) Serum tumor necrosis factor alpha (TNF-a) concentrations in SD-fed mice supplemented or not with SRT1720. Data are shown as mean ± SEM.
(F) Western blotting of liver lysates from SD-fed mice supplemented or not with SRT1720. Upper-left panel, representative blots; remaining panels, Signals
associated with bands of interest were normalized to GAPDH and plotted.
*p% 0.05; **p% 0.01; ***p% 0.001 in comparison to SD-fed control animals.In summary, we report data showing that SRT1720 elicits life-
span extension and improved healthspan in mice maintained
on a standard diet. This work highlights the importance of exam-
ining the therapeutic value of small molecule activators of SIRT1
in general health and longevity.
EXPERIMENTAL PROCEDURES
Animals and Diets
Male C57BL/6J mice were obtained from the Jackson Laboratory at 15 weeks
of age and housed at the Gerontology Research Center, in Baltimore, MD, in
cages of four. Diets were started at 28 weeks of age after randomization into
four groups of 100 mice per group. Mice were fed one of four diets: standard
diet (SD) of AIN-93G (carbohydrate:protein:fat ratio of 64:19:17 percent of
kcal), an SD supplemented with SRT1720 (SD-SRT1720), a high-fat diet
consisting of AIN-93G modified to provide 60% of calories from fat (HFD;
carbohydrate:protein:fat ratio of 16:23:61), or a HFD supplemented with
SRT1720 (HFD-SRT1720). SRT1720 was included in diets at a concentration
of 1.33 g/kg (SD) and 2 g/kg (HFD; g drug/kg chow), respectively, which was
formulated to provide mice with approximate daily doses of 100 mg/kg840 Cell Reports 6, 836–843, March 13, 2014 ª2014 The Authors(drug/kg body weight). Study diets were purchased from Dyets. SRT1720
was provided by Sirtris Pharmaceuticals. All groups had ad libitum access
to their prescribed diet and water throughout the study. Body weight and
food intake were monitored biweekly. Animal rooms were maintained at 20–
22C with 30%–70% relative humidity and a 12 hr light/dark cycle. All animal
protocols were approved by the Animal Care and Use Committee (352-LEG-
2012) of the National Institute on Aging.
Survival Study
Moribund animals were euthanized, and every animal found dead or eutha-
nized was necropsied. Additional information is available in the Supplemental
Information.
Histology
Organs were fixed in 4% paraformaldehyde then stained with hematoxylin and
eosin for scoring of pathology by a histopathologist blinded to the treatment
group.
Determination of Serum Marker Concentrations and HOMA-IR
Calculation
Detailed information can be found in the Supplemental Information.
Figure 4. SIRT1 Dependence in SRT1720-Mediated Gene Expres-
sion in MEF Cells
Microarray data collected from untreated (UT) and SRT1720-treated wild-type
(WT) and Sirt1-KO MEFs were used to illustrate enrichment of select genes. A
larger list of genes can be found in Table S6.Oral Glucose Tolerance Test
Following an overnight fast (18 hr), mice received an oral gavage of 30%
glucose solution (Sigma-Aldrich) at a dose of 2 g/kg body weight. Blood
glucose was measured using an Ascensia Elite glucose meter at 0, 15, 30,
60, and 120 min following gavage (n = 6 SD, n = 8 SD-SRT1720, 73 weeks
age, 46 weeks on diet).
Body Composition
Measurements of lean body mass, fat, and fluid mass in live mice were
acquired by nuclear magnetic resonance spectroscopy using the Minispec
LF90 (Bruker Optics) (n = 84 SD, n = 93 SD-SRT1720, n = 51 HFD, n = 73
HFD-SRT1720, 76 weeks age, 49 weeks on diet).
Metabolic Assessment
Mouse metabolic rate was assessed by indirect calorimetry in open-circuit
Oxymax chambers with CLAMS (Columbus Instruments) as previously
described (Minor et al., 2011) (n = 8 SD, n = 8 SD-SRT1720, n = 7 HFD,
n = 8 HFD-SRT1720, 52 weeks of age, 25 weeks on diet).
Rotarod
All mice were acclimated 15 min before testing. Mice were tested at the same
time of day during their light cycle over a 5-day period. Micewere given a habit-
uation trial at a constant speed of 4 rpm for 1 min before the first trial. On the
same day, there was a total of three trials given, separated by 30 min rest
periods, during which the rotarod accelerated from 4 to 40 rpm over a period
of 5 min. Latency to fall was recorded and averaged over all three trials. This
test was completed on the same mice at 13, 18, and 24 months of age.
Cataract Formation
Lens opacity reading was performed using a Kowa SL14 hand-held slit lamp
(Kowa) by an experienced pathologist blinded to the experimental group,
as described previously (Wolf et al., 2005) (n = 138 eyes SD, n = 142 eyes
SD-SRT1720, 105 weeks age, 78 weeks diet).
Western Blotting
Detailed information can be found in the Supplemental Information.
Microarray
RNA from tissues was isolated using the RNeasy kit (QIAGEN) and then
hybridized to BD-202-0202 Illumina BeadChips. Raw data were subjected toZ-normalization, as described elsewhere (Cheadle et al., 2003; Lee et al.,
2012). Additional information is available in the Supplemental Information.
Quantitative Real-Time RT-PCR
Total RNA was extracted from frozen tissue samples or cells using the RNeasy
kit (QIAGEN). Additional information can be found in the Supplemental
Information.
Phosphoprotein Profiling
The Phospho Explorer antibody microarray from Full Moon Biosystems was
used to survey the phosphorylation state of select proteins involved in the
IKK/NF-kB activation pathway, according to the protocol outlined in Bernier
et al. (2011). In brief, wild-type and Sirt1-KO murine embryonic fibroblasts
(gift of Raul Mostoslavsky, Harvard Medical School) were incubated with
vehicle or 3 mM SRT1720 for 18 hr, after which cell lysates were prepared
and biotinylated. The antibody array experiment was performed by Full
Moon Biosystems and the data were analyzedwith GenePix Pro 6.0 (Molecular
Devices). Each of the 1,318 antibodies had two replicates printed on a coated
microscope slide, along with multiple positive and negative controls.
Statistics
Data are expressed as means ± SEM. Student’s t tests were used for all
comparisons unless otherwise stated. Mortality during the survival study
was assessed through the use of the nonparametric log-rank (Mantel-
Haenszel) test to compare the differences in Kaplan-Meier survival curves.
Median survival was assessed using the nonparametric chi-square test (Su
andWei, 1993). Ninetieth percentile survival estimates were used as surrogate
measures of maximum survival times according to the methods of Wang et al.
(2004). The survival analyses were implemented in R (The RDevelopment Core
Team) from scratch using the methodological references given. Comparisons
for the histopathology data were performed using Fisher’s exact test. Analyses
were performed using Excel 2010 (Microsoft), IBM SPSS Statistics, or
SigmaStat 3.0 (Aspire Software International). A p value of% 0.05 was consid-
ered statistically significant.
ACCESSION NUMBERS
All raw data were deposited to the NCBI Gene Expression Omnibus under
accession number GSE50987.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and seven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.01.031.
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